Literature DB >> 17216219

Tumor budding as a prognostic marker in stage-III rectal carcinoma.

Hong-Jo Choi1, Ki-Jae Park, Jong-Sok Shin, Mee-Sook Roh, Hyuk-Chan Kwon, Hyung-Sik Lee.   

Abstract

BACKGROUND AND AIM: Tumor budding along the invasive margin is known to be associated with biological behavior in colorectal carcinoma. The aims of this study were to explore if the semiquantitative assessment of tumor budding in rectal cancers correlates with oncological behavior and to appraise if the tumor budding is valid as a pathological parameter in distinguishing tumors with higher malignancy potential from those with lower one for prognostic stratification.
MATERIALS AND METHODS: Surgical specimens from 244 patients with well- or moderately differentiated rectal carcinoma were retrieved to assess the intensity of tumor budding at the invasive margin. Intensities were divided semiquantitatively into four groups based on quartiles, and the 5-year disease-free survivals (DFS) were analyzed to search for a cutoff point of prognostic stratification.
RESULTS: The cutoff of the intensity considered to be the best indicator for dividing patients into subgroups with different DFS was between quartiles 3 and 4, but this survival difference in subgroups in either side of the cutoff was significant only in stage-III disease [5-year DFS, 62.1 vs 35.1%; p = 0.0023; 95% confidence interval (CI), 0.1824-0.6919]. Based on multivariate analysis, the intensity of budding proved to be an independent variable associated with DFS (hazard ratio, 2.005; p = 0.0086; 95% CI, 1.021-3.934). When scores were given to grade of budding (lower, 0; higher, 1) and N stage (N1, 0; N2, 1) in stage III, a better prognostic stratification in terms of the 5-year DFS was obtained than the American Joint Committee on Cancer nodal staging only (0 vs 1 vs 2, 66.5 vs 42.6 vs 29.2%; p = 0.0101).
CONCLUSIONS: Quantitative assessment of tumor budding is a reliable biological prognostic variable to identify higher malignancy potential. Scoring system using tumor budding and N stage showed better prognostic stratification in stage-III rectal carcinoma. A prospective evaluation would confirm the clinical significance of tumor budding for prognostic stratification.

Entities:  

Mesh:

Year:  2007        PMID: 17216219     DOI: 10.1007/s00384-006-0249-8

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.796


  23 in total

1.  Clinical implications of metastatic process.

Authors:  P Frost; B Levin
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

Review 2.  Reporting colorectal cancer.

Authors:  J R Jass; B C Morson
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

3.  Verification of a new clinicopathologic staging system for colorectal adenocarcinoma.

Authors:  F Michelassi; J J Ayala; T Balestracci; R Goldberg; R Chappell; G E Block
Journal:  Ann Surg       Date:  1991-07       Impact factor: 12.969

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Intensity of tumor budding and its prognostic implications in invasive colon carcinoma.

Authors:  Ki-Jae Park; Hong-Jo Choi; Mee-Sook Roh; Hyuk-Chan Kwon; Choongrak Kim
Journal:  Dis Colon Rectum       Date:  2005-08       Impact factor: 4.585

6.  Validation of a new classification system for curatively resected colorectal adenocarcinoma.

Authors:  A Sternberg; O Sibirsky; D Cohen; L E Blumenson; N J Petrelli
Journal:  Cancer       Date:  1999-09-01       Impact factor: 6.860

7.  Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma.

Authors:  Takashi Okuyama; Masatoshi Oya; Hiroshi Ishikawa
Journal:  J Surg Oncol       Date:  2003-05       Impact factor: 3.454

8.  Prognostic value of tumor "budding" in patients with colorectal cancer.

Authors:  K Hase; C Shatney; D Johnson; M Trollope; M Vierra
Journal:  Dis Colon Rectum       Date:  1993-07       Impact factor: 4.585

9.  Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.

Authors:  C Pyke; S Salo; E Ralfkiaer; J Rømer; K Danø; K Tryggvason
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

10.  Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.

Authors:  M Fujiya; J Watari; T Ashida; M Honda; H Tanabe; T Fujiki; Y Saitoh; Y Kohgo
Journal:  Jpn J Cancer Res       Date:  2001-10
View more
  28 in total

1.  Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

Authors:  Benedikt Martin; Eva Schäfer; Elzbieta Jakubowicz; Patrick Mayr; Regina Ihringer; Matthias Anthuber; Gerhard Schenkirsch; Tina Schaller; Bruno Märkl
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

2.  Tumour budding predicts increased recurrence after curative resection for T2N0 colorectal cancer

Authors:  Richard Garfinkle; Lawrence Lee; Marylise Boutros; Marie-Josee Cardin; Alan Spatz; Nancy Morin
Journal:  Can J Surg       Date:  2019-10-01       Impact factor: 2.089

Review 3.  Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis.

Authors:  F Petrelli; E Pezzica; M Cabiddu; A Coinu; K Borgonovo; M Ghilardi; V Lonati; D Corti; S Barni
Journal:  J Gastrointest Cancer       Date:  2015-09

Review 4.  Controversies in the pathological assessment of colorectal cancer.

Authors:  Aoife Maguire; Kieran Sheahan
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.

Authors:  Rondell P Graham; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Peter W Laird; Daniel J Weisenberger; Charles F Lynch; Amy J French; Susan L Slager; Yassaman Raissian; Joaquin J Garcia; Sarah E Kerr; Hee Eun Lee; Stephen N Thibodeau; James R Cerhan; Paul J Limburg; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

Review 6.  Meta-analysis of histopathological features of primary colorectal cancers that predict lymph node metastases.

Authors:  Sean C Glasgow; Joshua I S Bleier; Lawrence J Burgart; Charles O Finne; Ann C Lowry
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

7.  ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients.

Authors:  Lsabel Hostettler; Inti Zlobec; Luigi Terracciano; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

8.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

9.  CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer.

Authors:  A Lugli; E Karamitopoulou; I Panayiotides; P Karakitsos; G Rallis; G Peros; G Iezzi; G Spagnoli; M Bihl; L Terracciano; I Zlobec
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

10.  Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.

Authors:  Shigenobu Tatsumi; Hiroshi Matsuoka; Yumi Hashimoto; Kohei Hatta; Kotaro Maeda; Shingo Kamoshida
Journal:  Int J Clin Exp Pathol       Date:  2013-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.